Search
Filter Results
- Resource Type
- Article2
- Book1
- Book Print1
- Article Type
- Clinical Trial1
- Randomized Controlled Trial1
- Clinical Study1
- Controlled Clinical Trial1
- Result From
- PubMed2
- Lane Catalog1
-
Year
- Journal Title
- Oncotarget1
- PLoS One1
Search Results
Sort by
- ArticleCho KA, Park M, Kim YH, Ryu KH, Woo SY.Oncotarget. 2017 Oct 13;8(48):83419-83431.Th17 cells play a critical role in several autoimmune diseases, including psoriasis and psoriatic arthritis (PsA). Psoriasis is a chronic inflammatory skin disease associated with systemic inflammation and comorbidities, such as PsA. PsA develops in nearly 70% of patients with psoriasis, and osteoclasts associated bone erosion is a hallmark of the disease. Thus far, the effect of Th17 cells on osteoclastogenesis via direct cell-to-cell interactions is less understood. In this study, we observed that Th17 cells directly promote osteoclast differentiation and maturation via expression of receptor activator of nuclear factor-κ β ligand (RANKL) in vitro. We investigated the impact of conditioned medium obtained from human palatine tonsil-derived mesenchymal stem cells (T-CM) on the interactions between osteoclasts and Th17 cells. T-CM effectively blunted the RANK-RANKL interaction between the osteoclast precursor cell line RAW 264.7 and Th17 cells via osteoprotegerin (OPG) activity. The frequency of tartrate-resistant acid phosphatase (TRAP)-positive cells in the bone marrow of an imiquimod (IMQ)-induced psoriasis mouse model was decreased following T-CM injection. Therefore, our data provide novel insight into the therapeutic potential of tonsil-derived mesenchymal stem cell-mediated therapy (via OPG production) for the treatment of pathophysiologic processes induced by osteoclasts under chronic inflammatory conditions such as psoriasis.
- ArticleLuna J, Plata M, Gonzalez M, Correa A, Maldonado I, Nossa C, Radley D, Vuocolo S, Haupt RM, Saah A.PLoS One. 2013;8(12):e83431.BACKGROUND: Previous analyses from a randomized trial in women aged 24-45 have shown the quadrivalent HPV vaccine to be efficacious in the prevention of infection, cervical intraepithelial neoplasia (CIN) and external genital lesions (EGL) related to HPV 6/11/16/18 through 4 years. In this report we present long term follow-up data on the efficacy, safety and immunogenicity of the quadrivalent HPV vaccine in adult women.
METHODS: Follow-up data are from a study being conducted in 5 sites in Colombia designed to evaluate the long-term immunogenicity, effectiveness, and safety of the qHPV vaccine in women who were vaccinated at 24 to 45 years of age (in the original vaccine group during the base study [n = 684]) or 29 to 50 years of age (in the original placebo group during the base study [n = 651]). This analysis summarizes data collected as of the year 6 post-vaccination visit relative to day 1 of the base study (median follow-up of 6.26 years) from both the original base study and the Colombian follow-up.
RESULTS: There were no cases of HPV 6/11/16/18-related CIN or EGL during the extended follow-up phase in the per-protocol population. Immunogenicity persists against vaccine-related HPV types, and no evidence of HPV type replacement has been observed. No new serious adverse experiences have been reported.
CONCLUSIONS: Vaccination with qHPV vaccine provides generally safe and effective protection from HPV 6-, 11-, 16-, and 18-related genital warts and cervical dysplasia through 6 years following administration to 24-45 year-old women.
TRIAL REGISTRATION: Clinicaltrials.govNCT00090220. - BookThe Maudsley Deprescribing Guidelines : Antidepressants, Benzodiazepines, Gabapentinoids and z-drugsMark Horowitz, David Taylor.Summary: "The term 'deprescribing' originates from geriatric medicine where polypharmacy in frail patients can cause more harm than benefit.1 Deprescribing is increasingly recognised to be a key component of good prescribing - reducing doses when they are too high, and stopping medications when they are no longer needed.2 This process cannot occur in a vacuum of theoretical concerns but should take into account the patient's health, current level of functioning and, importantly, their values and preferences.1 Deprescribing seeks to apply best practice in prescribing to the process of stopping a medication. It requires the same skill and experience as for the process of prescribing from prescribers, as well as support from pharmacists and other healthcare staff to get the best results. Importantly, it should place patients at the centre of the process to ensure medicines optimisation"-- Provided by publisher.